Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Exact Sciences Corp Market Cap
From what 8 stock analysts predict, the share price for Exact Sciences Corp (EXAS) might increase by 46.36% in the next year. This is based on a 12-month average estimation for EXAS. Price targets go from $82.00 to $100.00. The majority of stock analysts believe EXAS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Exact Sciences Corp has a total of 8 Wall St Analyst ratings. There are 8 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Exact Sciences Corp will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| catherine ramsey schulte Robert W. Baird | Buy | $82.0 | maintained | Jan 29, 2024 |
| alexander nowak Craig-Hallum | Buy | None | rated | Jan 8, 2024 |
| bruce jackson Benchmark Co. | Buy | $91.0 | rated | Jan 8, 2024 |
| daniel arias Stifel Nicolaus | Buy | $100.0 | maintained | Jan 8, 2024 |
| puneet souda Leerink Partners | Buy | None | maintained | Jan 7, 2024 |
| derik de bruin Bank of America Securities | Buy | $88.0 | maintained | Jan 7, 2024 |
| mark massaro BTIG | Buy | $90.0 | maintained | Jan 1, 2024 |
| kyle mikson cfa Canaccord Genuity | Buy | $100.0 | maintained | Dec 19, 2023 |
| doug schenkel Wolfe Research | Buy | $95.0 | initiatedcoverage | Dec 12, 2023 |
| brandon couillard Jefferies | Buy | $95.0 | maintained | Nov 27, 2023 |
| david westenberg Piper Sandler | Buy | $80.0 | maintained | Nov 6, 2023 |
| matthew sykes Goldman Sachs | Buy | $90.0 | maintained | Nov 3, 2023 |
| patrick b donnelly Citi | Buy | $100.0 | maintained | Nov 2, 2023 |
| daniel brennan TD Cowen | Buy | $100.0 | maintained | Nov 1, 2023 |
| eve burstein Bernstein | Buy | $83.0 | initiatedcoverage | Sep 28, 2023 |
| dan leonard Credit Suisse | Hold | $90.0 | maintained | Aug 2, 2023 |
| vijay kumar Evercore ISI | Buy | $96.0 | maintained | Aug 2, 2023 |
| andrew brackmann William Blair | Buy | None | maintained | Jun 21, 2023 |
| andrew cooper Raymond James | Hold | None | downgraded | Jan 18, 2023 |
| kevin degeeter Oppenheimer | Buy | $155.0 | reiterated | Feb 23, 2022 |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
When did it IPO
2001
Staff Count
6,300
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Kevin T. Conroy
Market Cap
$11.35B
In 2023, EXAS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that EXAS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
BRKR-USD
$83.74
REG-USD
$60.81
GTLB-USD
$70.18
AZPN-USD
$179.8
AFRM-USD
$37.33
EVRG-USD
$50.61
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
